Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04433585 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT04433585: Completed Phase 2 study, sponsored by Nektar Therapeutics.
NCT04433585 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 291 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (119% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04433585, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Primary Outcome
Percentage of Participants who Achieved a ≥4 Point Reduction in SLEDAI-2K Score at Week 24. A SLEDAI-4 response is defined as a ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score from baseline. The SLEDAI-2K score range is from a minimum of 0 to a maximum of 105 (higher scores represent higher disease activity).
Interventions
- DRUG Placebo
- DRUG LY3471851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2023-02-16 |
| Phase | Phase 2 |
What the finished NCT04433585 record still lists
NCT04433585 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (119% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04433585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04433585 about?
NCT04433585 is a clinical study titled "A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)". The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
What is the current status of trial NCT04433585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2020-08-19. Estimated completion is 2023-02-16.
What interventions are being tested in trial NCT04433585?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).
Who is sponsoring clinical trial NCT04433585?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04433585's enrollment target sits among peer trials
291 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI